{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Incidence rate]",
                "outcomes": "[0.251]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Original analysis on rate ratio scale",
                    "Group": "TDF/FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11",
                    "Method": "Rate ratio analysis"
                },
                "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                "outcomes": "[0.251, REF]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Rate ratio]",
                "outcomes": "[REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Original analysis on rate ratio scale",
                    "Group": "TAF/FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6",
                    "Method": "Rate ratio analysis"
                },
                "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Rate ratio]",
                "outcomes": "[REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TDF/FTC",
                    "PYFU": "4386",
                    "Observed infections": "11",
                    "Predicted infections": "90.4",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[79.4, REF]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Rate ratio]",
                "outcomes": "[REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TAF-FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6"
                },
                "measures": "[Incidence rate]",
                "outcomes": "[0.137]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Original analysis on rate ratio scale",
                    "Group": "TAF/FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6",
                    "Method": "Rate ratio analysis"
                },
                "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TAF-FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6"
                },
                "measures": "[Rate ratio]",
                "outcomes": "[0.55 (0.20, 1.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TDF/FTC",
                    "PYFU": "4386",
                    "Observed infections": "11",
                    "Predicted infections": "90.4",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[79.4, REF]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TAF-FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6"
                },
                "measures": "[Rate ratio]",
                "outcomes": "[0.55 (0.20, 1.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Averted infections]",
                "outcomes": "[79.4]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TDF/FTC",
                    "PYFU": "4386",
                    "Observed infections": "11",
                    "Predicted infections": "90.4",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[79.4, REF]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TDF-FTC",
                    "PYFU": "4386",
                    "Incident HIV infections": "11"
                },
                "measures": "[Averted infections ratio]",
                "outcomes": "[REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TAF-FTC",
                    "PYFU": "4370",
                    "Incident HIV infections": "6"
                },
                "measures": "[Averted infections]",
                "outcomes": "[84.0]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "DISCOVER",
                    "Analysis": "primary outcome",
                    "Arm": "TAF-FTC",
                    "PYFU": "4370",
                    "Incident HIV infections": "6"
                },
                "measures": "[Averted infections ratio]",
                "outcomes": "[1.06 (0.96\u20131.17)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 12,
    "total_ground_truth_claims": 4,
    "number_of_matches": 4
}